Cargando…
Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma
BACKGROUND: Cyclin-dependent kinase subunit 2 (CKS2) is a member of cyclin dependent kinase subfamily and the relationship between CKS2 and osteosarcoma (OS) remains to be further analyzed. METHODS: 80 OS and 41 non-tumor tissue samples were arranged to perform immunohistochemistry (IHC) to evaluate...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004629/ https://www.ncbi.nlm.nih.gov/pubmed/35410253 http://dx.doi.org/10.1186/s12920-022-01234-8 |
_version_ | 1784686306461220864 |
---|---|
author | Mo, Chaohua Wu, Yanxing Ma, Jie Xie, Le Huang, Yingxin Xu, Yuanyuan Peng, Huizhi Chen, Zengwei Zeng, Min Mao, Rongjun |
author_facet | Mo, Chaohua Wu, Yanxing Ma, Jie Xie, Le Huang, Yingxin Xu, Yuanyuan Peng, Huizhi Chen, Zengwei Zeng, Min Mao, Rongjun |
author_sort | Mo, Chaohua |
collection | PubMed |
description | BACKGROUND: Cyclin-dependent kinase subunit 2 (CKS2) is a member of cyclin dependent kinase subfamily and the relationship between CKS2 and osteosarcoma (OS) remains to be further analyzed. METHODS: 80 OS and 41 non-tumor tissue samples were arranged to perform immunohistochemistry (IHC) to evaluate CKS2 expression between OS and non-tumor samples. The standard mean deviation (SMD) was calculated based on in-house IHC and tissue microarrays, and exterior high-throughput datasets for further verification of CKS2 expression trend in OS. The effect of CKS2 expression on clinicopathological parameters of OS patients, and single-cell in OS tissues was analyzed through public high-throughput datasets and functional enrichment analysis was conducted for co-expression genes of CKS2 in accordance with weighted correlation network analysis. RESULTS: A total of 217 OS samples and 87 non-tumor samples (including tissue and cell line) were obtained from in-house IHC, microarrays and exterior high-throughput datasets. The analysis of integrated expression status demonstrated up-regulation of CKS2 in OS (SMD = 1.57, 95%CI [0.27–2.86]) and the significant power of CKS2 expression in distinguishing OS samples from non-tumor samples (AUC = 0.97 95%CI [0.95–0.98]). Clinicopathological analysis of GSE21257 indicated that OS patients with higher CKS2 expression was more likely to suffer OS metastasis. Although Kaplan–Meier curves showed no remarkable difference of overall survival rate between OS patients with high and low-CKS2, CKS2 was found up-regulated in proliferating osteosarcoma cells. Co-expression genes of CKS2 were mainly assembled in function and pathways such as cell cycle, cell adhesion, and intercellular material transport. CONCLUSIONS: In summary, up-regulation of CKS2 expression in OS tissue was found through multiple technical approaches. In addition, scRNA-seq and co-expression analysis showed that CKS2 may have an impact on important biological process linked with cell cycle, cell adhesion, and intercellular material transport. Present study on CKS2 in OS indicated a promising prospect for CKS2 as a biomarker for OS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-022-01234-8. |
format | Online Article Text |
id | pubmed-9004629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90046292022-04-13 Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma Mo, Chaohua Wu, Yanxing Ma, Jie Xie, Le Huang, Yingxin Xu, Yuanyuan Peng, Huizhi Chen, Zengwei Zeng, Min Mao, Rongjun BMC Med Genomics Research BACKGROUND: Cyclin-dependent kinase subunit 2 (CKS2) is a member of cyclin dependent kinase subfamily and the relationship between CKS2 and osteosarcoma (OS) remains to be further analyzed. METHODS: 80 OS and 41 non-tumor tissue samples were arranged to perform immunohistochemistry (IHC) to evaluate CKS2 expression between OS and non-tumor samples. The standard mean deviation (SMD) was calculated based on in-house IHC and tissue microarrays, and exterior high-throughput datasets for further verification of CKS2 expression trend in OS. The effect of CKS2 expression on clinicopathological parameters of OS patients, and single-cell in OS tissues was analyzed through public high-throughput datasets and functional enrichment analysis was conducted for co-expression genes of CKS2 in accordance with weighted correlation network analysis. RESULTS: A total of 217 OS samples and 87 non-tumor samples (including tissue and cell line) were obtained from in-house IHC, microarrays and exterior high-throughput datasets. The analysis of integrated expression status demonstrated up-regulation of CKS2 in OS (SMD = 1.57, 95%CI [0.27–2.86]) and the significant power of CKS2 expression in distinguishing OS samples from non-tumor samples (AUC = 0.97 95%CI [0.95–0.98]). Clinicopathological analysis of GSE21257 indicated that OS patients with higher CKS2 expression was more likely to suffer OS metastasis. Although Kaplan–Meier curves showed no remarkable difference of overall survival rate between OS patients with high and low-CKS2, CKS2 was found up-regulated in proliferating osteosarcoma cells. Co-expression genes of CKS2 were mainly assembled in function and pathways such as cell cycle, cell adhesion, and intercellular material transport. CONCLUSIONS: In summary, up-regulation of CKS2 expression in OS tissue was found through multiple technical approaches. In addition, scRNA-seq and co-expression analysis showed that CKS2 may have an impact on important biological process linked with cell cycle, cell adhesion, and intercellular material transport. Present study on CKS2 in OS indicated a promising prospect for CKS2 as a biomarker for OS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-022-01234-8. BioMed Central 2022-04-11 /pmc/articles/PMC9004629/ /pubmed/35410253 http://dx.doi.org/10.1186/s12920-022-01234-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mo, Chaohua Wu, Yanxing Ma, Jie Xie, Le Huang, Yingxin Xu, Yuanyuan Peng, Huizhi Chen, Zengwei Zeng, Min Mao, Rongjun Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma |
title | Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma |
title_full | Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma |
title_fullStr | Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma |
title_full_unstemmed | Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma |
title_short | Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma |
title_sort | clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004629/ https://www.ncbi.nlm.nih.gov/pubmed/35410253 http://dx.doi.org/10.1186/s12920-022-01234-8 |
work_keys_str_mv | AT mochaohua clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma AT wuyanxing clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma AT majie clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma AT xiele clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma AT huangyingxin clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma AT xuyuanyuan clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma AT penghuizhi clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma AT chenzengwei clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma AT zengmin clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma AT maorongjun clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma |